Feasibility and timing of unrelated donor identification for patients with ALL

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 737-740

  Davies, S M ^a,b   Ramsay, N K C ^a   Weisdorf, D J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

Acute lymphoblastic leukemia; Bone marrow donor registry; Bone marrow transplantation; Unrelated donor

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CYTOGENETICS; HEALTH CARE POLICY; HEALTH INSURANCE; HISTOCOMPATIBILITY TEST; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; ORGAN DONOR; PATIENT COUNSELING; PATIENT REFERRAL; PRIORITY JOURNAL; RISK FACTOR; SIBLING; TIME; TREATMENT OUTCOME;

BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVING DONORS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0029931440     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hussein KK, Dahlberg S, Head D et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57-63.
2. Henze G, Fengler R, Hartmann R et al. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 1991; 78: 1166-1172.
3. Gaynon PS, Bleyer WA, Albo VC et al. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Lancet 1988; 2: 921-924.
4. Bloomfield CD, Goldman AI, Alimena G et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood 1986; 67: 415-420.
5. Trueworthy R, Shuster J, Look T et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992; 10: 606-613.
6. Pui C-H, Dodge RK, Look AT et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St Jude total therapy studies VIII, IX, and X. J Clin Oncol 1991; 9: 1341-1347.
7. Ramsay NKC, Kersey JH. Indications for marrow transplantation in acute lymphoblastic leukemia. Blood 1990; 75: 815-818.
8. Linker CA, Levitt LJ. O'Donnell M et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78: 2814-2822.
9. Dopfer R, Henze G, Bender-Götze C et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study. Blood 1991; 78: 2780-2784.
10. Barrett AJ, Horowitz MM, Gale RP et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74: 862-871.
11. Busca A, Anasetti C, Anderson G et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 1994; 83: 3077-3084.
12. Stroncek D, Bartsch G, Perkins HA et al. The National Marrow Donor Program. Transfusion 1993; 33: 567-577.
13. Anasetti C, Howe C, Petersdorf EW et al. Marrow transplants from HLA matched unrelated donors: an NMDP update and the Seattle experience. Bone Marrow Transplant 1994; 13: 693-695.
14. Howard MR, Gore SM, Hows JM et al. A prospective study of factors determining the outcome of unrelated marrow donor searches: report from the International Marrow Unrelated Search and Transplant Study Working Group on behalf of collaborating centres. Bone Marrow Transplant 1994; 13: 389-396.